10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...
The Harvard Crimson1d
Harvard, 10x Genomics Settle Patent Dispute With Vizgen
Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...
Analysts Set 10x Genomics, Inc. (NASDAQ:TXG) Target Price at $20.57
Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...
Seeking Alpha8d
TXG 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company ... as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes ...
10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan Stanley
Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...
Forbes3d
10x Genomics
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
10x Genomics price target lowered to $18 from $19 at Barclays
Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...
10x, Harvard settle genomics patent dispute with Vizgen during trial
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...